PURPOSE OF REVIEW: Systemic lupus erythematosus is characterized by the production of antinuclear autoantibodies and dysfunction of T-cells, B-cells, and dendritic cells. Here, we review newly recognized genetic factors and mechanisms that underlie abnormal intracellular signal processing and intercellular communication within the immune system in systemic lupus erythematosus. RECENT FINDINGS: Activation of the mammalian target of rapamycin plays a pivotal role in abnormal activation of T and B-cells in systemic lupus erythematosus. In T-cells, increased production of nitric oxide and mitochondrial hyperpolarization were identified as metabolic checkpoints upstream of mammalian target of rapamycin activation. Mammalian target of rapamycin controls the expression T-cell receptor-associated signaling proteins CD4 and CD3zeta through increased expression of the endosome recycling regulator HRES-1/Rab4 gene, mediates enhanced Ca2+ fluxing and skews the expression of tyrosine kinases both in T and B-cells, and blocks the expression of Foxp3 and the expansion of regulatory T-cells. Mitochondrial hyperpolarization and the resultant ATP depletion predispose T-cells to necrosis, thus promoting the dendritic cell activation, antinuclear autoantibody production, and inflammation. SUMMARY: Mitochondrial hyperpolarization, increased activity of mammalian target of rapamycin and Syk kinases, enhanced receptor recycling and Ca2+ flux have emerged as common T and B-cell biomarkers and targets for treatment in systemic lupus erythematosus.
PURPOSE OF REVIEW: Systemic lupus erythematosus is characterized by the production of antinuclear autoantibodies and dysfunction of T-cells, B-cells, and dendritic cells. Here, we review newly recognized genetic factors and mechanisms that underlie abnormal intracellular signal processing and intercellular communication within the immune system in systemic lupus erythematosus. RECENT FINDINGS: Activation of the mammalian target of rapamycin plays a pivotal role in abnormal activation of T and B-cells in systemic lupus erythematosus. In T-cells, increased production of nitric oxide and mitochondrial hyperpolarization were identified as metabolic checkpoints upstream of mammalian target of rapamycin activation. Mammalian target of rapamycin controls the expression T-cell receptor-associated signaling proteins CD4 and CD3zeta through increased expression of the endosome recycling regulator HRES-1/Rab4 gene, mediates enhanced Ca2+ fluxing and skews the expression of tyrosine kinases both in T and B-cells, and blocks the expression of Foxp3 and the expansion of regulatory T-cells. Mitochondrial hyperpolarization and the resultant ATP depletion predispose T-cells to necrosis, thus promoting the dendritic cell activation, antinuclear autoantibody production, and inflammation. SUMMARY: Mitochondrial hyperpolarization, increased activity of mammalian target of rapamycin and Syk kinases, enhanced receptor recycling and Ca2+ flux have emerged as common T and B-cell biomarkers and targets for treatment in systemic lupus erythematosus.
Authors: Domingo F Barber; Almira Bartolomé; Carmen Hernandez; Juana M Flores; Cristina Fernandez-Arias; Luis Rodríguez-Borlado; Emilio Hirsch; Matthias Wymann; Dimitrios Balomenos; Ana C Carrera Journal: J Immunol Date: 2006-01-01 Impact factor: 5.422
Authors: Maurits Demedts; Juergen Behr; Roland Buhl; Ulrich Costabel; Richard Dekhuijzen; Henk M Jansen; William MacNee; Michiel Thomeer; Benoit Wallaert; François Laurent; Andrew G Nicholson; Eric K Verbeken; Johny Verschakelen; Christopher D R Flower; Frédérique Capron; Stefano Petruzzelli; Paul De Vuyst; Jules M M van den Bosch; Eulogio Rodriguez-Becerra; Giuseppina Corvasce; Ida Lankhorst; Marco Sardina; Mauro Montanari Journal: N Engl J Med Date: 2005-11-24 Impact factor: 91.245
Authors: R Andres Floto; Menna R Clatworthy; Karen R Heilbronn; Dalya R Rosner; Paul A MacAry; Angela Rankin; Paul J Lehner; Willem H Ouwehand; Janet M Allen; Nicholas A Watkins; Kenneth G C Smith Journal: Nat Med Date: 2005-09-18 Impact factor: 53.440
Authors: Sales Ibiza; Víctor M Víctor; Irene Boscá; Angel Ortega; Ana Urzainqui; José E O'Connor; Francisco Sánchez-Madrid; Juan V Esplugues; Juan M Serrador Journal: Immunity Date: 2006-06 Impact factor: 31.745
Authors: Liang Ma; Kwok-Wah Chan; Nigel J Trendell-Smith; Adrian Wu; Lina Tian; Audrey C Lam; Albert K Chan; Chi-Kin Lo; Stanley Chik; King-Hung Ko; Christina K W To; Siu-Kee Kam; Xiao-Song Li; Cui-Hong Yang; Suet Yi Leung; Mun-Hon Ng; David I Stott; G Gordon MacPherson; Fang-Ping Huang Journal: Eur J Immunol Date: 2005-11 Impact factor: 5.532
Authors: Lingchen Fu; Yen-Chiu Lin-Lee; Lan V Pham; Archito Tamayo; Linda Yoshimura; Richard J Ford Journal: Blood Date: 2006-02-23 Impact factor: 22.113
Authors: Y-T Juang; C Peoples; R Kafri; V C Kyttaris; K Sunahori; K Kis-Toth; L Fitzgerald; S Ergin; M Finnell; G C Tsokos Journal: Lupus Date: 2010-12-07 Impact factor: 2.911
Authors: Deanna R Brickley; Abena S Agyeman; Richard F Kopp; Ben A Hall; Mark C Harbeck; Larissa Belova; Paul A Volden; Wei Wu; Michael W Roe; Suzanne D Conzen Journal: J Biol Chem Date: 2013-09-16 Impact factor: 5.157
Authors: György Nagy; Agnes Koncz; Tiffany Telarico; David Fernandez; Barbara Ersek; Edit Buzás; András Perl Journal: Arthritis Res Ther Date: 2010-06-28 Impact factor: 5.156